ZB131 ADC Induce Potent Anti-tumor Activity CSP-expressing Tumors

Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).

Results of Preclinical Data for GQ1010 Confirm Potential for Best-In-Class TROP2-Targeted Antibody Drug Conjugate

The trophoblast cell surface antigen 2 (TROP2), a transmembrane glycoprotein that plays a role in cell self-renewal, proliferation, and transformation and survival, is overexpressed in many forms of cancers independent of baseline levels of TROP2 expression.

AACR 2023: Preclinical Data Highlights Stable and Efficacious Low Drug-Load ADCs

Two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida, highlight late-breaking preclinical data from studies with an anti-Nectin-4 ADC and anti-HER2 ADC.

X